Dynamics of Aβ42 reduction in plasma, CSF and brain of rats treated with the γ-secretase modulator, GSM-10h

Neurodegenerative Diseases

Volumn 8, Issue 6, 2011, Pages 455-464

  Hawkins, Julie ^a   Harrison, David C ^a   Ahmed, Sharlin ^a   Davis, Robert P ^a   Chapman, Trevor ^a   Marshall, Ian ^a   Smith, Beverley ^a   Mead, Tania L ^a   Medhurst, Andrew ^a   Giblin, Ged M P ^a   Hall, Adrian ^a   Gonzalez, Maria I ^a   Richardson, Jill ^a   Hussain, Ishrut ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Secretase; Alzheimer's disease; Amyloid ; Modulator; Rat

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; GSM 10H; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; EMBRYO; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ACETIC ACIDS; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN CHEMISTRY; CELL COUNT; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOMEODOMAIN PROTEINS; MALE; NEURONS; PEPTIDE FRAGMENTS; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NOTCH; RNA, MESSENGER; SIGNAL TRANSDUCTION; THYMUS GLAND;

EID: 79960566232     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000324511     Document Type: Article

References (32)

1. Glenner GG, Wong CW: Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Comm 1984; 120: 885-890. (Pubitemid 14104991)
2. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A: Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988; 85: 4051-4055.
3. Selkoe DJ: Cell biology of the amyloid betaprotein precursor and the mechanism of Alzheimers disease. Annu Rev Cell Biol 1994; 10: 373-403. (Pubitemid 24372824)
4. Hardy JA, Higgins GA: Alzheimers disease: the amyloid cascade hypothesis. Science 1992; 256: 184-185.
5. Jarrett JT, Berger EP, Lansbury PT Jr: The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimers disease. Biochemistry 1993; 32: 4693-4697. (Pubitemid 23162022)
6. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL: Diffusible, nonfibrillar ligands derived from A1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998; 95: 6448-6453.
7. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ: Protofibrillar intermediates of amyloid -protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999; 19: 8876-8884. (Pubitemid 30226709)
8. Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ: Oligomeric and fibrillar species of amyloid-peptides differentially affect neuronal viability. J Biol Chem 2002; 277: 32046-32053. (Pubitemid 34969015)
9. Götz J, Chen F, van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491-1495. (Pubitemid 32807681)
10. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimers disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimers disease. Nat Med 1992; 2: 864-870. (Pubitemid 26296755)
11. Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J: Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res 2008; 5: 121-131. (Pubitemid 351536337)
12. Milano J, McKay J, Dagenais C, Foster- Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ: Modulation of Notch processing by-secretase inhibitors causes intestinal goblet metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-358. (Pubitemid 39485346)
13. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, Zhang L, Higgins GA, Parker EM: Chronic treatment with the- secretase inhibitor LY-411,575 inhibits- amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882. (Pubitemid 38445862)
14. Beher D: Gamma-secretase modulation and its promise for Alzheimers disease: a rationale for drug discovery. Curr Top Med Chem 2008; 8: 34-37. (Pubitemid 351791044)
15. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH: A subset of NSAIDs lower amyloidogenic A42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216. (Pubitemid 33051236)
16. Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH: Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R -flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 2007; 21: 292-299. (Pubitemid 350307433)
17. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, Tarenflurbil Phase II Study investigators: Efficacy and safety of tarenflurbil in mild to moderate Alzheimers disease: a randomised phase II trial. Lancet Neurol 2008; 7: 483-493.
18. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase 3 Study Group: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009; 302: 2557-2564.
19. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE: NSAIDs and enantiomers of flurbiprofen target gamma- secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-449. (Pubitemid 38063773)
20. Hall A, Elliott RL, Giblin GM, Hussain I, Musgrave J, Naylor A, Sasse R, Smith B: Piperidine- derived gamma-secretase modulators. Bioorg Med Chem Lett 2009; 20: 1306-1311.
21. Hussain I, Harrison DC, Hawkins J, Chapman T, Marshall I, Facci L, Ahmed S, Brackenborough K, Skaper SD, Mead TL, Smith BB, Giblin GM, Hall A, Gonzalez MI, Richardson JC: TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to gammasecretase modulation and amyloid-beta(42) lowering by GSM-10h. Neurodegener Dis 2011; 8: 15-24.
22. Skaper SD, Facci L, Milani D, Leon A, Toffano G: Culture and use of primary and clonal neural cells; in Conn PM (ed): Methods in Neurosciences. San Diego, Academic Press, 1990, vol 2, pp 17-33.
23. Best JD, Jay MT, Otu F, Ma J, Nadin A, Ellis S, Lewis HD, Pattison C, Reilly M, Harrison T, Shearman MS, Williamson TL, Atack JR: Quantitative measurement of changes in amyloid-(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N 2 - [2(S)-2-(3,5-Dif luorophenyl)-2-hydroxyethanoyl]- N 1 -[(7S)-5-methyl-6-oxo-6,7- dihydro-5H-dibenzo[ b,d ]azepin-7-yl]- L - alaninamide]. J Pharmacol Exp Ther 2005; 313: 902-908. (Pubitemid 40604194)
24. Best JD, Jay MT, Otu F, Churcher I, Reilly M, Morentin-Gutierrez P, Pattison C, Harrison T, Shearman MS, Atack JR: In vivo characterization of Abeta(40) changes in brain and CSF using the novel gamma-secretase inhibitor MRK-560 (N-[cis-4-[(4-chlorophenyl) sulfonyl]-4-(2,5-dif luorophenyl)cyclohexyl] - 1,1,1-trifluoromethanesulfonamide) in the rat. J Pharmacol Exp Ther 2006; 317: 786-790.
25. Kageyama R, Ohtsuka T, Tomita K: The bHLH Gene Hes1 Regulates differentiation of multiple cell types. Mol Cells 2000; 10: 1-7.
26. Robey E, Chang D, Itano A, Cado D, Alexander H, Lans D, Weinmaster G, Salmon P: An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell 1996; 87: 483-492. (Pubitemid 26374322)
27. Imbimbo BP: Therapeutic potential of gamma- secretase inhibitors and modulators. Curr Top Med Chem 2008; 8: 54-61. (Pubitemid 351791047)
28. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM: Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12: 856-861. (Pubitemid 44050079)
29. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, Ness D, May PC: Safety, tolerability, and changes in amyloid B concentrations after administration of a- secretase inhibitor in volunteers. Clin Neuropharmacol 2005; 28: 126-132. (Pubitemid 40923411)
30. Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KE, Finley JE, Fei Q, Ebbinghaus CF, Chen YL, Spracklin DK, Tate B, Geoghegan KF, Lau LF, Auperin DD, Schachter JB: Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006; 319: 924-933.
31. Siemers E, Dean RA, Friedrich S, Ferguson- Sells L, Gonzales C, Farlow MR, May PC: Safety, Tolerability, and Effects on Plasma and Cerebrospinal Fluid Amyloid-After Inhibition of-Secretase. Clin Neuropharmacol 2007; 30: 317-325. (Pubitemid 350307310)
32. Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS: GSI-953 (begacestat): a novel, selective thiophene sulfonamide inhibitor of APP gamma-secretase for the treatment of Alzheimers disease: J Pharmacol Exp Ther 2009; 331: 598-608.